Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Q2 2018 Earnings Presentation
16 slides from Niagen Bioscience's earnings presentation, Aug 9, 2018
Slide 1: Earnings Conference Call Second Quarter 2018
Earnings Conference Call Second Quarter 2018 Frank Jaksch — Co-Founder ~ [executive Chairman ie = Rob Fried — ceo Kevin Farr - cro
Slide 2: etait et tna reenter ele eter wet om
etait et tna reenter ele eter wet om ciara see es
Slide 3: Science Continues to Expand
—— Science Continues to Expand * 22 human studies on nicotinamide riboside in various stages * The University of Copenhagen and Aarhus University Hospital * Long-term safety * NIAGEN effectively increases NAD levels * Potential for improvement in liver health * 156 MTAs signed with research institut
Slide 4: Recent Peer-Reviewed Publications
Recent Peer-Reviewed Publications + eLIFE ~ Davila(Baur) ~ “Nicotinamide adenine dinucleotide is transported into mammalian mitochondria” = June 2018 ‘+ Free Radical Biology Medicine ~ Hong ~ “Administration of nicotinamide riboside prevents oxidative stress and organ” = June 2018 ‘+ Cell Reports -
Slide 5: Growth of TRU NIAGEN exceeds plan
Growth of &f) TRUNIAGEN exceeds plan * TRU NIAGEN sales show strong growth + Net sales were up 85% ‘+ TRU NIAGEN accounted for 66% of total NIAGEN-related sales vs. 7% last year *+ E-commerce sales of TRU NIAGEN in the U.S. compounding at over 259% month/month + NIAGEN-Related sales up 168% Year-ove
Slide 6: Building a Global Brand
buicing a Global Brand
Slide 7: Management Team
Management Team Rob Fried ~ Chief Executive Ofcer Board member since 2015, President, CEO and Director of ideation Acquisition Corp. 2009-2011, Founder and CEO of Feein 2007-2017 (acquired by Hallmark Cards Inc. in 2012), and Academy Award and Emmy Award winning motion picture produce Frank Jaksch-
Slide 8: Financial Highlights
Slide 9: Sales by channel
commerce Watsons Intemational / Other Total TRU MAGEN NIAGEN ingredient
Slide 10: Q2 2018 Net Sales Up 85% to $7.8 Million, Fueled by Growth of TRU NIAGEN
Q2 2018 Net Sales Up 85% to $7.8 Million, Fueled by Growth of TRU NIAGEN® + TRU NIAGEN sales were 66% of total NIAGEN-related sales in Q2 2018 + NIAGEN-related sales in Q2 2018 grew 168% compared to Q2 2017 + NIAGEN-related sales in Q2 2018 were 73% of total sales, compared to 50% in Q2 2017 218 nel
Slide 11: NIAGEN Related Sales – Q2 2017 vs. Q2 2018, +168%
NIAGEN Related Sales ~ Q2 2017 vs. Q2 2018, +168%
Slide 12: 2018 Profit and Loss
— ~ 2018 Profit and Loss Send Quiros
Slide 13: Q2 2017 Operating Loss vs. Q2 2018
—_—— Q2 2017 Operating Loss vs. Q2 2018 iy ton a mm owe sae = es. = S95 2 = 5s
Slide 14: 2018 First Half Net Cash Used in Operating Activities
2018 First Half Net Cash Used in Operating Activities
Slide 15: 2018 Outlook
2018 Outlook ificant growth in revenues + Gross profit % of net sales continues to expand + Investment spending ahead of revenue growth + Marketing + More focused R&D + Protecting/managing patent portfolio and trademarks * Overall net losses and cash outflows to moderate in second half of the year +
Slide 16: Contact Info
—— Contact Info Andrew Johnson Director of investor Relations T: #1.310.388,6706 Ext. 661 Andrew\@chromadexcom ‘wwn.chromadex.com